| SC 13G | 2022-06-10 | Deep Track Capital, LP | Nurix Therapeutics, Inc. | 2,436,164 | 5.2% | EDGAR |
| SC 13G/A | 2022-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Nurix Therapeutics, Inc. | 4,871,084 | 10.9% | EDGAR |
| SC 13G/A | 2022-02-14 | Redmile Group, LLC | Nurix Therapeutics, Inc. | 2,958,284 | 6.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Third Rock Ventures III, L.P. | Nurix Therapeutics, Inc. | 2,422,549 | 5.4% | EDGAR |
| SC 13G | 2022-02-14 | BAKER BROS. ADVISORS LP | Nurix Therapeutics, Inc. | 2,454,082 | 5.5% | EDGAR |
| SC 13G/A | 2022-02-11 | Foresite Capital Fund IV, L.P. | Nurix Therapeutics, Inc. | 1,205,798 | 2.7% | EDGAR |
| SC 13G/A | 2022-02-11 | COLUMN GROUP L P | Nurix Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Nurix Therapeutics, Inc. | 1,162,316 | 2.6% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | Nurix Therapeutics, Inc. | 2,547,861 | 5.7% | EDGAR |
| SC 13G | 2021-08-10 | PRICE T ROWE ASSOCIATES INC /MD/ | Nurix Therapeutics, Inc. | 4,626,895 | 10.4% | EDGAR |
| SC 13G/A | 2021-02-16 | Foresite Capital Fund IV, L.P. | Nurix Therapeutics, Inc. | 2,347,804 | 6.0% | EDGAR |
| SC 13G | 2021-02-16 | Redmile Group, LLC | Nurix Therapeutics, Inc. | 2,846,125 | 7.3% | EDGAR |
| SC 13G | 2021-02-16 | COLUMN GROUP L P | Nurix Therapeutics, Inc. | 3,394,333 | 8.7% | EDGAR |
| SC 13G | 2021-02-16 | Third Rock Ventures III, L.P. | Nurix Therapeutics, Inc. | 5,422,549 | 14.0% | EDGAR |
| SC 13G/A | 2021-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Nurix Therapeutics, Inc. | 2,447,584 | 6.3% | EDGAR |
| SC 13G | 2020-08-10 | WELLINGTON MANAGEMENT GROUP LLP | Nurix Therapeutics, Inc. | 4,075,980 | 10.8% | EDGAR |
| SC 13G | 2020-08-03 | Foresite Capital Fund IV, L.P. | Nurix Therapeutics, Inc. | 2,320,784 | 6.3% | EDGAR |